Rheumatoid Arthritis, biological agents policy - Pan Mersey APC Skip to main content Help with accessibility Skip to main navigation

Rheumatoid Arthritis, biological agents policy

Last Updated: 24 February 2016

Body System: Musculoskeletal system

Red

The Pan Mersey Area Prescribing Committee recommends the use of abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and tocilizumab in the management of rheumatoid arthritis in accordance with NICE TA375.